Spasticity Patient Services - Healthcare Professionals

Do your patients need help with reimbursement and insurance coverage for Zanaflex Capsules^® (tizanidine hydrochloride)?

Reimbursement Program

The Zanaflex Capsules^® (tizanidine hydrochloride) Reimbursement Program is designed to help you help your patients work through the insurance reimbursement process with as few complications as possible.

Call the Zanaflex Capsules^® (tizanidine hydrochloride) Reimbursement Hotline toll-free at 1-800-464-0097 from 10am to 6pm Eastern Time, Monday through Friday

Be prepared to provide the following information:

Office Contact Information
Physicians Name
Address
Phone and Fax
Contact Person for Office
Provider Number for the Patient’s Plan

Patient Information
Plan Name, Member ID #
SS # and Date of Birth
Address and Phone #
Correct Diagnosis Codes
Previous Meds/Failed or Not Tolerated
Zanaflex Capsules Rx Information (2,4,or 6mg and frequency)

The Reimbursement Program will complete the necessary paperwork
for the Insurance Plan or Medicaid and will fax to your office for a physician signature and a copy of the prescription.

The Reimbursement Program will send the Prior Authorization(P.A) request form to the
plan and follow up by phone to inquire about status.

The Reimbursement Program will follow up with your practice and patients (if requested) to indicate the decision has been received.

Assistance Program

The Zanaflex Capsules^® (tizanidine hydrochloride) Assistance Program is designed to help patients who do not have insurance and whose income falls within the specific guidelines. The patient advocates at the toll-free number listed above will be able to help your patients with the application process for this program.

Acorda Therapeutics, Inc., the makers of Zanaflex Capsules^® (tizanidine hydrochloride), is committed to protecting patient privacy. Any information provided to the patient advocates will not be sold or used for any marketing solicitations by Acorda Therapeutics, Inc., or any of its affiliates.

For samples or medical information, Call toll free 1-800-367-5109

Please see below for Important Safety Information.

Be sure your patient received what you prescribed

Zanaflex Capsules® (tizanidine hydrochloride) is a short-acting drug indicated for the management of spasticity. Because of the short duration of effect, treatment with Zanaflex Capsules® (tizanidine hydrochloride) should be reserved for those daily activities and times when relief of spasticity is most important.

Important Safety Information:

Use with fluvoxamine or ciprofloxacin is contraindicated and results in significant increases in tizanidine plasma levels.
There is a limited data base for chronic use of single doses above 8 mg and multiple doses above 24 mg per day.
Tizanidine is an alpha2-adrenergic agonist and can produce hypotension. In a single-dose study where patients were not titrated, two-thirds of patients given 8 mg of Zanaflex experienced hypotension, which may be minimized by titration of dose. The hypotensive effect is dose related and has been measured following single doses of 2 mg or more.
Tizanidine occasionally causes liver injury, most often of the hepatocellular type.
Patients should be advised that sedation may interfere with daily activities. These effects appear to be dose related.
Visual hallucinations or delusions occurred in 3% (5/170) of study patients in two North American clinical trials.
Use with caution in hepatic or renally impaired patients.
Use with oral contraceptives results in 50% decrease in tizanidine clearance.
To discontinue therapy, taper the dose in patients receiving high doses over long time periods to reduce the risk of hypertension, tachycardia and hypertonia.
In vitro studies indicate that neither tizanidine nor the major metabolites are likely to affect the metabolism of other drugs metabolized by cytochrome P450 isoenzymes.
Most common adverse events with tizanidine include dry mouth (49%), somnolence (48%), asthenia [weakness, fatigue and/or tiredness] (41%), dizziness (16%) and increased ALT (5%). Other adverse events include UTI, infection and constipation.
Food has complex effects on tizanidine pharmacokinetics, which differ for the different formulations. These pharmacokinetic differences may result in clinically significant differences when switching formulations, or changing administration during a fed or fasted state. These changes may result in increased adverse events or a delayed/more rapid onset of activity, depending on the nature of the switch.

For Full Prescribing Information - Click Here Information For Patients Guide - Click Here

Do your patients need help with reimbursement and insurance coverage for Zanaflex Capsules® (tizanidine hydrochloride)?

Reimbursement Program

Assistance Program

Do your patients need help with reimbursement and insurance coverage for Zanaflex Capsules^® (tizanidine hydrochloride)?